OTCPK:KMLX.F

Stock Analysis Report

Executive Summary

Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Respiri has significant price volatility in the past 3 months.
  • Respiri is not covered by any analysts.

Share Price & News

How has Respiri's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:KMLX.F

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:KMLX.F

9.1%

US Medical Equipment

2.0%

US Market

No trading data on KMLX.F.

No trading data on KMLX.F.


Share holder returns

KMLX.FIndustryMarket
7 Day0%-0.9%1.3%
30 Day-21.3%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Yearn/a70.7%65.5%47.2%37.6%
5 Year-41.0%-41.0%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Respiri's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Respiri undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Respiri is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Respiri has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of KMLX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Respiri regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Respiri expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of KMLX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Respiri's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Respiri performed over the past 5 years?

12.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Respiri does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Respiri's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Respiri's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Respiri has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Respiri has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Respiri improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Respiri's financial position?


Financial Position Analysis

Respiri's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Respiri has no long term commitments.


Debt to Equity History and Analysis

Respiri has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Respiri's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Respiri has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Respiri has less than a year of cash runway based on current free cash flow.

Respiri has less than a year of cash runway if free cash flow continues to grow at historical rates of 28.5% each year.


Next Steps

Dividend

What is Respiri's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Respiri's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Respiri's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Respiri has not reported any payouts.

Unable to verify if Respiri's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Respiri has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Respiri's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Mario Gattino 0

1.8yrs

Tenure

AU$492,832

Compensation

Mr. Mario Gattino serves as Executive Director of Respiri Limited since December 14, 2017. He has been the Chief Executive Officer at Respiri Limited since December 1, 2017. Mr. Gattino served as Country C ...


CEO Compensation Analysis

Mario's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Mario to compare compensation growth.


Management Age and Tenure

1.5yrs

Average Tenure

The average tenure for the Respiri management team is less than 2 years, this suggests a new team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jan Barker

    Vice-President of Business Development

    • Tenure: 7.7yrs
  • Noam Gavriely

    Medical & Scientific Advisor

    • Tenure: 0yrs
    • Compensation: AU$310.61k
  • Simon Godfrey

    Medical & Scientific Advisor

    • Tenure: 0yrs
  • Mario Gattino

    CEO & Executive Director

    • Tenure: 1.8yrs
    • Compensation: AU$492.83k
  • Wani Wall

    Chief Customer Experience & Communications Officer

    • Tenure: 1.2yrs
  • Samaneh Sarraf

    Chief Research Officer

    • Tenure: 0yrs
  • Alastair Beard

    Company Secretary

    • Tenure: 0.5yrs

Board Members

  • Ross James Blair-Holt

    Non-Executive Chairman

    • Tenure: 0.8yrs
    • Compensation: AU$11.38k
  • Mario Gattino

    CEO & Executive Director

    • Tenure: 1.8yrs
    • Compensation: AU$492.83k
  • Bruce Thompson

    Non-Executive Director and Chair of the Medical & Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Respiri Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Respiri Limited
  • Ticker: KMLX.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$49.741m
  • Listing Market Cap: AU$34.261m
  • Shares outstanding: 558.88m
  • Website: https://respiri.co

Location

  • Respiri Limited
  • 101 Collins Street
  • Level 27
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RSHASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 2006
KMLX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2006
RSHCHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 2006

Biography

Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel. The company produces and sells mobile health applications. Its product ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:10
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.